WO2007095976A3 - Adjuvanz in form einer lipid-modifizierten nukleinsäure - Google Patents
Adjuvanz in form einer lipid-modifizierten nukleinsäure Download PDFInfo
- Publication number
- WO2007095976A3 WO2007095976A3 PCT/EP2006/008321 EP2006008321W WO2007095976A3 WO 2007095976 A3 WO2007095976 A3 WO 2007095976A3 EP 2006008321 W EP2006008321 W EP 2006008321W WO 2007095976 A3 WO2007095976 A3 WO 2007095976A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adjuvant
- relates
- lipid
- nucleic acid
- modified nucleic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Die vorliegende Erfindung betrifft ein immunstimulierendes Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure, optional in Kombination mit weiteren Adjuvanzien. Des weiteren betrifft die Erfindung eine pharmazeutische Zusammensetzung und eine Vakzine, jeweils enthaltend ein erfindungsgemäßes immunstimulierendes Adjuvanz, mindestens einen Wirkstoff und optional einen pharmazeutisch geeigneten Träger und/oder weitere Hilfs- und Zusatzstoffe und/oder weitere Adjuvanzien. Die vorliegende Erfindung betrifft ebenfalls die Verwendung der erfindungsgemäßen pharmazeutischen Zusammensetzung sowie der erfindungsgemäßen Vakzine zur Behandlung von Infektionserkrankungen oder Krebserkrankungen. Ebenso umfasst die vorliegende Erfindung die Verwendung des erfindungsgemäßen immunstimulierenden Adjuvanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Krebserkrankungen oder Infektionserkrankungen.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/748,181 US20070280929A1 (en) | 2006-02-17 | 2007-05-14 | Adjuvant in the form of a lipid-modified nucleic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006007433.5 | 2006-02-17 | ||
DE102006007433A DE102006007433A1 (de) | 2006-02-17 | 2006-02-17 | Adjuvanz in Form einer Lipid-modifizierten Nukleinsäure |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/748,181 Continuation-In-Part US20070280929A1 (en) | 2006-02-17 | 2007-05-14 | Adjuvant in the form of a lipid-modified nucleic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007095976A2 WO2007095976A2 (de) | 2007-08-30 |
WO2007095976A3 true WO2007095976A3 (de) | 2007-11-01 |
Family
ID=37891885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/008321 WO2007095976A2 (de) | 2006-02-17 | 2006-08-24 | Adjuvanz in form einer lipid-modifizierten nukleinsäure |
Country Status (3)
Country | Link |
---|---|
US (1) | US20070280929A1 (de) |
DE (1) | DE102006007433A1 (de) |
WO (1) | WO2007095976A2 (de) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
WO2004053104A2 (en) | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
DK2578685T3 (da) | 2005-08-23 | 2019-06-03 | Univ Pennsylvania | Rna indeholende modificerede nukleosider og fremgangsmåder til anvendelse deraf |
AU2007280690C1 (en) | 2006-07-31 | 2012-08-23 | Curevac Gmbh | Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant |
DE102006035618A1 (de) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
CN101517082B (zh) | 2006-09-27 | 2014-01-22 | 科勒制药有限责任公司 | 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物 |
WO2009030254A1 (en) * | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
EP2548960B1 (de) | 2008-01-31 | 2018-01-31 | CureVac AG | Nukleinsäure der Formel (NuGIXmGnNv)a und Derivate davon als immunstimulierendes Mittel/Adjuvans |
US8728465B2 (en) | 2008-06-17 | 2014-05-20 | Cedars-Sinai Medical Center | Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
WO2010075525A1 (en) * | 2008-12-24 | 2010-07-01 | Cedars-Sinai Medical Center | Method of using tumor cell debris to reduce brain tumor recurrence or growth |
DE102009034779A1 (de) | 2009-07-25 | 2011-02-03 | Emc Microcollections Gmbh | Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
SG186706A1 (en) | 2010-07-30 | 2013-02-28 | Curevac Gmbh | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
EP2600901B1 (de) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | Pharmazeutische zusammensetzungen enthaltenbearbeitete nukleinsäuren und ihre medizinische verwendung |
ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN102351932A (zh) * | 2011-07-07 | 2012-02-15 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种抗流感病毒寡核苷酸的结构、制备方法和用途 |
CN102295673A (zh) * | 2011-07-07 | 2011-12-28 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 一种脂肪链修饰的寡核苷酸的结构、制备方法及用途 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
US9650407B2 (en) | 2011-11-02 | 2017-05-16 | The Regents Of The University Of California | Reprogramming of cellular adhesion |
EP2791160B1 (de) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modifizierte mrna zusammensetzungen |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
EP4074834A1 (de) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Am kettenende modifizierte rna |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AU2014310934B2 (en) | 2013-08-21 | 2019-09-12 | CureVac SE | Respiratory syncytial virus (RSV) vaccine |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
BR112016024644A2 (pt) | 2014-04-23 | 2017-10-10 | Modernatx Inc | vacinas de ácido nucleico |
EP3461904A1 (de) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nukleinsäuremoleküle mit reduziertem uracilgehalt und verwendungen davon |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
WO2016193206A1 (en) | 2015-05-29 | 2016-12-08 | Curevac Ag | A method for producing and purifying rna, comprising at least one step of tangential flow filtration |
US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
EP3324979B1 (de) | 2015-07-21 | 2022-10-12 | ModernaTX, Inc. | Impfstoffe gegen infektionserkrankungen |
PT3350157T (pt) | 2015-09-17 | 2022-03-18 | Modernatx Inc | Compostos e composições para administração intracelular de agentes terapêuticos |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
EP3362460A1 (de) | 2015-10-16 | 2018-08-22 | Modernatx, Inc. | Mrna-kappenanaloga und verfahren zum mrna-kappen |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
WO2017066797A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Trinucleotide mrna cap analogs |
EP3364981A4 (de) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | Impfstoff gegen das humane cytomegalovirus |
CA3002819A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Sexually transmitted disease vaccines |
EP3364950A4 (de) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | Impfstoffe gegen tropenkrankheiten |
EP4011451A1 (de) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Impfstoffe gegen atemwegsvirus |
CA3002912A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
EP3373965A1 (de) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus-impfstoffe |
AU2016377681B2 (en) | 2015-12-22 | 2021-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
WO2018089540A1 (en) | 2016-11-08 | 2018-05-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
MA47787A (fr) | 2017-03-15 | 2020-01-22 | Modernatx Inc | Vaccin contre le virus respiratoire syncytial |
US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
PL3596041T3 (pl) | 2017-03-15 | 2023-03-06 | Modernatx, Inc. | Związek i kompozycje do dokomórkowego dostarczania środków terapeutycznych |
MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR PREPARING MODIFIED RNA |
WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
US10653767B2 (en) | 2017-09-14 | 2020-05-19 | Modernatx, Inc. | Zika virus MRNA vaccines |
JP2021512044A (ja) * | 2017-11-02 | 2021-05-13 | ヤンセン バイオファーマ インク. | オリゴヌクレオチドコンストラクト及びその使用 |
TWI818943B (zh) * | 2018-01-04 | 2023-10-21 | 中央研究院 | 用於增加療效之可與細胞結合的免疫佐劑 |
MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
JP7410135B2 (ja) | 2018-09-19 | 2024-01-09 | モデルナティエックス インコーポレイテッド | 治療薬の細胞内送達のための化合物及び組成物 |
CA3113651A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
CN113710353A (zh) | 2019-01-31 | 2021-11-26 | 摩登纳特斯有限公司 | 涡流混合器及其相关方法、系统和装置 |
BR112021014845A2 (pt) | 2019-01-31 | 2021-11-03 | Modernatx Inc | Métodos de preparação de nanopartículas lipídicas |
US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
CN114206827B (zh) | 2020-04-09 | 2023-05-23 | 苏州艾博生物科技有限公司 | 脂质纳米颗粒组合物 |
TW202204622A (zh) | 2020-04-09 | 2022-02-01 | 大陸商蘇州艾博生物科技有限公司 | 針對冠狀病毒之核酸疫苗 |
EP4164753A1 (de) | 2020-06-30 | 2023-04-19 | Suzhou Abogen Biosciences Co., Ltd. | Lipidverbindungen und lipidnanopartikelzusammensetzungen |
JP2023537887A (ja) | 2020-08-20 | 2023-09-06 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
WO2022152141A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Polymer conjugated lipid compounds and lipid nanoparticle compositions |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
KR20240013087A (ko) | 2021-05-24 | 2024-01-30 | 쑤저우 아보젠 바이오사이언시스 컴퍼니 리미티드 | 지질 화합물 및 지질 나노입자 조성물 |
CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
WO2023044343A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
EP4204391A1 (de) | 2021-10-08 | 2023-07-05 | Suzhou Abogen Biosciences Co., Ltd. | Lipidverbindungen und lipidnanopartikelzusammensetzungen |
CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US20030225016A1 (en) * | 2001-06-21 | 2003-12-04 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same - III |
WO2004004743A1 (de) * | 2002-07-03 | 2004-01-15 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte rna |
EP1393745A1 (de) * | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden |
WO2004058159A2 (en) * | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
WO2005030259A2 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU776268B2 (en) * | 1999-06-08 | 2004-09-02 | Aventis Pasteur | Immunostimulant oligonucleotide |
CA2521662A1 (en) * | 2003-04-10 | 2005-01-06 | 3M Innovative Properties Company | Methods and compositions for enhancing immune response |
-
2006
- 2006-02-17 DE DE102006007433A patent/DE102006007433A1/de not_active Withdrawn
- 2006-08-24 WO PCT/EP2006/008321 patent/WO2007095976A2/de active Application Filing
-
2007
- 2007-05-14 US US11/748,181 patent/US20070280929A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) * | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030225016A1 (en) * | 2001-06-21 | 2003-12-04 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same - III |
WO2003066649A1 (en) * | 2002-02-04 | 2003-08-14 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
WO2004004743A1 (de) * | 2002-07-03 | 2004-01-15 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte rna |
EP1393745A1 (de) * | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulierung der immunstimulierenden Eigenschaften von Oligonukleotiden und Analoga durch optimale Darstellung der 5'-Enden |
WO2004058159A2 (en) * | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
WO2005030259A2 (en) * | 2003-09-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
WO2006116458A2 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhances immunostimulatory activity |
Non-Patent Citations (4)
Title |
---|
BAYARD B ET AL: "ANTIVIRAL ACTIVITY IN L-1210 CELLS OF LIPOSOME-ENCAPSULATED 2'-5' OLIGOADENYLATE ANALOGS", EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 151, no. 2, 1985, pages 319 - 326, XP002440943, ISSN: 0014-2956 * |
HAUSCH F ET AL: "A Novel Carboxy-functionalized Photocleavable Dinucleotide Analog for the Selection of RNA Catalysts", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 39, no. 34, 20 August 1998 (1998-08-20), pages 6157 - 6158, XP004128903, ISSN: 0040-4039 * |
KWIATKOWSKI, M. ET AL: "The 9-(4- octadecyloxyphenylxanthen )-9-yl-group. A new acid-labile hydroxyl protective group and its application in the preparative reverse-phase chromatographic separation of oligoribonucleotides", ACTA CHEMICA SCANDINAVICA, SERIES B: ORGANIC CHEMISTRY AND BIOCHEMISTRY , B38(8), 657-71 CODEN: ACBOCV; ISSN: 0302-4369, 1984, XP009086061 * |
SHEA R G ET AL: "Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 18, no. 13, 1990, pages 3777 - 3783, XP002244700, ISSN: 0305-1048 * |
Also Published As
Publication number | Publication date |
---|---|
DE102006007433A1 (de) | 2007-08-23 |
WO2007095976A2 (de) | 2007-08-30 |
US20070280929A1 (en) | 2007-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007095976A3 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
CY1121211T1 (el) | Εμβολιο ιου ερπητα ζωστηρα | |
WO2008014979A3 (en) | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT | |
WO2007054279A3 (en) | Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions | |
WO2006040076A3 (de) | Impf-adjuvanzien pam3cys, poly (i:c), imiquimod, loxoribine, r-848 und cpg-dna zusammen mit mhc i oder mhc ii epitopen | |
WO2007057763A3 (en) | Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant | |
WO2006029081A3 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
WO2002080965A3 (en) | Vaccine composition | |
JP2016513638A5 (de) | ||
WO2007024941A3 (en) | Polyvalent vaccine | |
WO2006085983A3 (en) | Viral adjuvants | |
GB0025577D0 (en) | Vaccine | |
HK1044484A1 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide. | |
WO2008096831A1 (ja) | 癌の治療剤 | |
WO2008084294A3 (en) | Methods of vaccine administration | |
WO2009060281A3 (en) | Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties | |
WO2009135199A3 (en) | Vaccine compositions and methods | |
WO2021154812A8 (en) | Coronavirus vaccine formulations | |
SG178904A1 (en) | Combination vaccines against respiratory tract diseases | |
WO2007059931A8 (en) | New adjuvants on the basis of bisacyloxypropylcysteine conjugates and derivatives and their uses in pharmaceutical compositions | |
WO2009076158A8 (en) | Compositions for inducing immune responses | |
WO2009080715A3 (en) | Vaccines for malaria | |
WO2005121378A3 (en) | Methods and compositions for vaccination | |
WO2004026260A3 (en) | Prophylactic and therapeutic hiv aptamers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 11748181 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 11748181 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06791641 Country of ref document: EP Kind code of ref document: A2 |